Literature DB >> 15448023

Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.

Ronald M Bukowski1, Sylvie Negrier, Paul Elson.   

Abstract

The identification of prognostic factors in patients with metastatic renal cell carcinoma represents an area of increasing interest. Multiple publications identifying pertinent clinical and laboratory variables have appeared since 1986. The current study of 353 patients with advanced disease treated at The Cleveland Clinic from 1987 to 2002 was conducted to additionally assess and validate a model proposed recently by investigators from Memorial Sloan-Kettering Cancer Center. The data presented are similar to those reported previously, which demonstrated that patients with metastatic renal cell carcinoma can be categorized into good-, intermediate-, and poor-risk groups, using readily available clinical factors. Additionally, comparability of patients in this database to a group treated recently in France was assessed. These two groups appear similar in their distribution of various clinical factors and survival. Finally, a group of international investigators has been developed to provide a comprehensive database of >4,000 patients with metastatic renal cell carcinoma to provide and validate a single model that can be used to predict survival. This project is now under way.

Entities:  

Mesh:

Year:  2004        PMID: 15448023     DOI: 10.1158/1078-0432.CCR-050000

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].

Authors:  C Doehn; A S Merseburger; D Jocham; M A Kuczyk
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

Review 2.  Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma.

Authors:  Elisa Zanardi; Elena Verzoni; Paolo Grassi; Andrea Necchi; Patrizia Giannatempo; Daniele Raggi; Filippo De Braud; Giuseppe Procopio
Journal:  Ther Adv Urol       Date:  2015-06

3.  Systemic therapy for advanced renal cell carcinoma.

Authors:  James M G Larkin; Emma L S Kipps; Ceri J Powell; Charles Swanton
Journal:  Ther Adv Med Oncol       Date:  2009-07       Impact factor: 8.168

Review 4.  Adjuvant therapy for renal cell carcinoma.

Authors:  Naomi B Haas; Robert Uzzo
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

5.  Stability of preclinical models of aggressive renal cell carcinomas.

Authors:  Mariana Varna; Guilhem Bousquet; Irmine Ferreira; Marie Goulard; Morad El-Bouchtaoui; Pierre Mongiat Artus; Jérome Verine; Eric de Kerviler; Lucie Hernandez; Christophe Leboeuf; Bernard Escudier; Luc Legrès; Niclas Setterblad; Hany Soliman; Jean-Paul Feugeas; Anne Janin; Philippe Bertheau
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients.

Authors:  Hailiang Zhang; Dingwei Ye; Xudong Yao; Bo Dai; Shilin Zhang; Yijun Shen; Yao Zhu; Huirong Mao
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-23       Impact factor: 4.553

7.  Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience.

Authors:  Simrit Parmar; Alfred W Rademaker; Bing B Fung; James M Kozlowski; Timothy M Kuzel
Journal:  Med Oncol       Date:  2005       Impact factor: 3.738

8.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec

9.  Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.

Authors:  Juping Zhao; Xin Huang; Fukang Sun; Renyi Ma; Haofei Wang; Kun Shao; Yu Zhu; Wenlong Zhou; Zhaoping Xu; Zhoujun Shen
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

10.  MicroRNA-148b enhances proliferation and apoptosis in human renal cancer cells via directly targeting MAP3K9.

Authors:  Fang Nie; Tianming Liu; Liang Zhong; Xianggui Yang; Yunhong Liu; Hongwei Xia; Xiaoqiang Liu; Xiaoyan Wang; Zhicheng Liu; Li Zhou; Zhaomin Mao; Qin Zhou; Tingmei Chen
Journal:  Mol Med Rep       Date:  2015-11-11       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.